Overview

NS1209 and Lidocaine in Patients With Peripheral Neuropathic Pain

Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
0
Participant gender:
All
Summary
Purpose: To evaluate the efficacy, tolerability and safety of NS1209 compared to lidocaine and placebo in patients with peripheral chronic neuropathic pain.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Danish Pain Research Center
Collaborator:
NeuroSearch A/S
Treatments:
Lidocaine
Criteria
Inclusion Criteria:

- Age >18 years

- Neuropathic pain and allodynia after a peripheral nerve injury (VAS >= 4)

Exclusion Criteria:

- Patients who cannot cooperate and do no understand Danish

- Fertile women

- Clinically significant abnormality or disease

- Drug and alcohol abuse

- Clinically abnormal ECG

- Hypersensitivity to any of the treatments

- Patients in treatment with cimetedin, antidepressants, antipsychotics, antiepileptics
except gabapentin, anticoagulants, Na channel blockers and beta blockers

- Patients who have previously been treated in a NS1209 study

- Patients treated with an investigational drug